School readiness program for preschool children with sickle cell disease
Official title: School Readiness Intervention for Preschool Children With Sickle Cell Disease
Run by St. Jude Children's Research Hospital · NCT06367192 · Data updated 2026-11-12
This study is testing a special online school readiness program for preschool kids with sickle cell disease to see if it helps them get ready for school better than regular resources.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 42 Months to 78 Months |
| Sex | All |
| Enrollment | 36 (estimated) |
| Sponsor | St. Jude Children's Research Hospital Academic / other |
| Locations | 1 site (Memphis, Tennessee) |
| Status | Recruiting |
| Started | March 31, 2025 |
| Main results expected | October 2026 |
| Study ends | October 2028 |
| Registry record updated | April 24, 2026 |
| Trial ID | NCT06367192 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are preschool children aged 3.5 to 6.5 years with a diagnosis of sickle cell disease and their English-speaking caregivers.
✕Probably not a fit
Patients who do not have sickle cell disease or are non-English speakers may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates a school readiness intervention designed specifically for preschool children aged 3.5 to 6.5 years diagnosed with sickle cell disease. Participants will be randomly assigned to either the intervention group, which will attend virtual classroom sessions over eight weeks, or to a control group receiving standard school resources. The study aims to assess the feasibility and acceptability of the program, as well as its preliminary efficacy in improving school readiness skills compared to routine care. Caregivers will also provide feedback through interviews and assessments will be conducted to measure various outcomes before and after the intervention.
Why it matters
Potential benefit: If successful, this program could enhance school readiness and educational outcomes for children with sickle cell disease.
How similar studies have gone: While similar interventions have been explored, this specific adaptation for children with sickle cell disease is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Diagnosed with sickle cell disease of any genotype. * Enrolled on the institutional protocol: Sickle Cell Clinical Research Intervention Program (SCCRIP) * Age 3.5-6.5 years inclusive at the time of enrollment * English as the primary language * Research participant and one parent willing to participate and provide consent/assent according to institutional guidelines Caregiver Participants * Have a child diagnosed with SCD of any genotype between the ages of 3.5-6.5 years and enrolled in SCCRIP * English as the primary language Exclusion Criteria * Do not have a child diagnosed with SCD of any genotype between the ages of 3.5-6.5 years and enrolled in SCCRIP * Non-English speakers
Where it's running
-
St. Jude Children's Research Hospital
Memphis, Tennessee, United States Recruiting
Study contacts
- Principal investigator: ANDREW Heitzer, PhD — St. Jude Children's Research Hospital
- Study coordinator: ANDREW HEITZER, PhD
- Email: referralinfo@stjude.org
- Phone: 888-226-4343
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cerebrovascular Reactivity Testing with HD-DOT in Sickle Cell Patients
This study tests whether high-density diffuse optical tomography can measure brain blood flow and oxygen use in people with sickle cell disease, to see how these signals relate to stroke risk.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
Newborn Sickle Cell Screening in Mozambique
We’re testing a three-part plan to help babies in Mozambique get diagnosed early for sickle cell disease and start care quickly.
-
Optimizing Hydroxyurea in Children with Sickle Cell in Africa
This study tests whether raising hydroxyurea to a maximum tolerated dose is safe and beneficial for Ugandan children with sickle cell anemia already taking a fixed daily dose.
-
Hematopoietic stem cell editing to treat sickle cell disease
This study tests whether a patient’s own blood stem cells can be edited to remove the sickle cell triggering gene and then returned to the patient.
-
Virtual reality options to help with VOC pain in adults with SCD
This study tests whether headset-based virtual reality can help reduce pain for adults with sickle cell disease during vaso-occlusive crises treated in an infusion center.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.